BR112022020012A2 - Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas - Google Patents

Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas

Info

Publication number
BR112022020012A2
BR112022020012A2 BR112022020012A BR112022020012A BR112022020012A2 BR 112022020012 A2 BR112022020012 A2 BR 112022020012A2 BR 112022020012 A BR112022020012 A BR 112022020012A BR 112022020012 A BR112022020012 A BR 112022020012A BR 112022020012 A2 BR112022020012 A2 BR 112022020012A2
Authority
BR
Brazil
Prior art keywords
hepe
compositions
methods
prevention
treatment
Prior art date
Application number
BR112022020012A
Other languages
English (en)
Inventor
Climax John
Hamza Moayed
Weissbach Markus
Coughlan David
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of BR112022020012A2 publication Critical patent/BR112022020012A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSIÇÕES QUE COMPREENDEM 15-HEPE E MÉTODOS DE TRATAMENTO OU PREVENÇÃO DE DISTÚRBIOS HEMATOLÓGICOS E/OU DOENÇAS RELACIONADAS. A presente divulgação refere-se a métodos de tratamento ou prevenção de distúrbios hematológicos por administração de 15-HEPE ou composições do mesmo.
BR112022020012A 2020-04-03 2020-04-03 Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas BR112022020012A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/059682 WO2021197639A1 (en) 2020-04-03 2020-04-03 Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases

Publications (1)

Publication Number Publication Date
BR112022020012A2 true BR112022020012A2 (pt) 2022-12-13

Family

ID=70189967

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020012A BR112022020012A2 (pt) 2020-04-03 2020-04-03 Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas

Country Status (10)

Country Link
EP (1) EP4125854A1 (pt)
JP (1) JP2023528562A (pt)
KR (1) KR20220163468A (pt)
CN (1) CN115715192A (pt)
AU (1) AU2020440809A1 (pt)
BR (1) BR112022020012A2 (pt)
CA (1) CA3179158A1 (pt)
IL (1) IL297114A (pt)
MX (1) MX2022012404A (pt)
WO (1) WO2021197639A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022090482A1 (en) * 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof
US20240299328A1 (en) * 2023-03-06 2024-09-12 Afimmune Limited Compositions comprising 15-hepe and methods of treating and/or preventing hematologic disorders and related diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296923B3 (en) * 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
CN112245420A (zh) * 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物

Also Published As

Publication number Publication date
AU2020440809A1 (en) 2022-11-10
IL297114A (en) 2022-12-01
WO2021197639A1 (en) 2021-10-07
JP2023528562A (ja) 2023-07-05
CN115715192A (zh) 2023-02-24
MX2022012404A (es) 2023-02-09
EP4125854A1 (en) 2023-02-08
KR20220163468A (ko) 2022-12-09
CA3179158A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
TR201910765T4 (tr) Bitkisel hülasaların bir karışımını veya bu bitkilerde mevcut moleküllerin bir karışımını içeren bileşim ve karbonhidrat ve/veya lipit metabolizmasını etkilemek için kullanımı.
BR112018013522A2 (pt) compostos inibidores de metaloenzima
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112014013963A8 (pt) compostos inibidores de metaloenzimas
BR112022010086A2 (pt) Dosagem do inibidor de shp2 e métodos de tratamento de câncer
BR112022015110A2 (pt) Compostos e usos dos mesmos
BR112021018687A2 (pt) Combinação de dose fixa de canabinoides e cogumelos medicinais para prevenção e tratamento de câncer, doenças inflamatórias ou inflamatórias imunomediadas
BR112022020012A2 (pt) Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
BR112021018591A2 (pt) Compostos e usos dos mesmos
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
BR112022014949A2 (pt) Compostos e usos dos mesmos
BR112022015109A2 (pt) Compostos e usos dos mesmos
BR112022020683A2 (pt) Anticorpos e composições anti-flt3
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112022013480A2 (pt) Métodos de tratamento de coronavírus
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112022025128A2 (pt) Composições e métodos para tratar doenças e distúrbios usando vesículas extracelulares microbianas de oscillospiraceae
BR112022005896A2 (pt) Inibidores da mek para o tratamento de infecções causadas por hantavírus
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.